Please assess the completion status of the following clinical trial:

Trial Title: Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18 - 65 years inclusive at the time of screening.~* Patients must be receiving a first cadaveric or living donor renal transplant.~* Patients must be able to receive oral medication at time of randomization.~* Females who are not pregnant or nursing or planning to become pregnant during the course of the study, or 3 months after last dose of study medication.~* Sexually-active women of child-bearing potential (including those who are \< 1 year postmenopausal) and sexually-active men who are practicing a highly effective method of birth control. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly and will include implants, injectables, combined oral contraceptives, double-barrier method, sexual abstinence, or a sterile partner. Sexually-active men and women of child-bearing potential should continue to practice contraception as outlined above during treatment and for ≥ 3 months after the last dose of voclosporin.~* Able to give written informed consent prior to screening procedures.~* Able to keep study appointments and cooperate with all study requirements, in the opinion of the investigator.~Exclusion Criteria:~* Receiving a HLA (human leukocyte antigen)identical living related transplant.~* Cold ischemic time \> 24 hours.~* Peak PRA (panel reactive antibodies) \> 30%~* Cadaveric donors who are over age 60, non-heart beating donors, or any cadaveric donors positive for HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV).~* Transplantation of multiple grafts (e.g. kidney and pancreas).~* Systemic infections requiring continued therapy at the time of entry into this study. (Prophylaxis against cytomegalovirus \[CMV\] and/or pneumocystis carinii pneumonia (PCP) infection will be permitted).~* Serologic evidence or known latent human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) virus. Known negative serology prior to study entry may be used.~* A current malignancy or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.~* Requires prohibited medications or treatment during the study.~* Alanine transaminase (ALT), aspartate transaminase (AST), or gamma-glutamyl transferase (GGT) ≥ 3x upper limit of normal (ULN) at time of transplantation.~* White blood cell count ≤ 2.8 x 10\^9/L.~* Triglycerides ≥ 3x ULN.~* Pregnant women or nursing mothers.~* Has used any investigational drug or device within 28 days or 5 half lives (whichever is longer) prior to enrollment.~* Previous exposure to voclosporin.~* A history of active alcoholism or drug addiction within 1 year prior to study entry.~* Weighs \< 45 kg (99 lbs) or \> 140 kg (308 lbs).~* A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, or that might cause the administration of voclosporin to pose a significant risk to the subject, in the opinion of the investigator.~* Allergy to iodine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Voclosporin (Type: ACTIVE_COMPARATOR): Low dose voclosporin
- Mid Dose Voclosporin (Type: ACTIVE_COMPARATOR): Mid Dose Voclosporin
- High Dose Voclosporin (Type: ACTIVE_COMPARATOR): High Dose Voclosporin
- Tacrolimus (Type: ACTIVE_COMPARATOR): Standard Dose Tacrolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).